Aripiprazole Tablet
Product Images NDC 43547-889

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43547-889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2 (2f5cad93 Figure 02)

This description provides information on the potential effects of various drugs on Aripiprazole metabolism through interactions with specific enzymes such as CYP3A4 and CYP2D6. Additionally, the text mentions the influence of gastric acid blockers and other drugs like valproate and lorazepam on Aripiprazole. The table shows the fold change in Dehydro-Aripiprazole levels in the presence of different interacting drugs compared to the reference condition.*

FDA Label Image

Figure 3 (2f5cad93 Figure 03)

This text discusses the effect of aripiprazole on various other drugs by presenting the fold change and 90% confidence intervals for CYP2S enzymes. It lists several drugs such as omeprazole, valproate, lorazepam, venlafaxine, and desmethylvenlafaxine, along with their corresponding AUC values. The text provides a comparison of the drugs' effects relative to a reference drug without interacting drugs.*

FDA Label Image

Figure 4 (2f5cad93 Figure 04)

This text appears to be a list of special populations and conditions related to drug metabolism and effects. It includes information about gender, age, hepatic impairment, and potential changes in drug levels. It seems to be detailing factors that could impact the way drugs are processed in the body.*

FDA Label Image

Figure 5 (2f5cad93 Figure 05)

This is a chart showing the fold change and confidence intervals for Dehydro-Aripiprazole among different values of change relative to the reference. It includes comparison by gender (female vs. male) and age group. The data appears to be related to a study or analysis involving Dehydro-Aripiprazole.*

FDA Label Image

Figure 6 (2f5cad93 Figure 06)

This text provides information related to a clinical trial comparing the relapse rates of Aripiprazole and Placebo over a period of time. The data includes the number of subjects at risk for each treatment, allowing for the analysis of the proportion with relapse on different days from randomization. This information can be useful for evaluating the effectiveness of Aripiprazole in preventing relapse compared to Placebo.*

FDA Label Image

Figure 7 (2f5cad93 Figure 07)

This text provides information on the proportion with relapse for Aripiprazole and Placebo treatments. It also includes the number of subjects at risk on different days from randomization.*

FDA Label Image

Figure 8 (2f5cad93 Figure 08)

FDA Label Image

10 mg 30 Ct (Arpiprazole 10mg 100count)

This text provides information on Aripiprazole tablets containing 10 mg. It includes instructions to refer to the package insert for indications and dosage details. The storage conditions are specified as between 20°C to 25°C with excursions permitted between 15°C to 30°C. The manufacturer is Prinston Laboratories, Charlotte, USA, and it is distributed by Solco Healthcare US, LLC, Somerset USA. For more details, the website mentioned can be visited.*

FDA Label Image

15 mg 30 Ct (Arpiprazole 15mg 100count)

This text provides information about a medication called Aripiprazole, which is available in tablets containing 15 mg of the active ingredient. The text instructs to refer to the accompanying package insert for indications and dosage information. It also indicates the storage conditions for the tablets and provides a website for printing the medication guide. The manufacturing and distribution details of the medication are also provided.*

FDA Label Image

20 mg 30 Ct (Arpiprazole 20mg 100count)

This text provides information about Aripiprazole tablets, each containing 20 mg of the active ingredient. The package insert should be consulted for indications and dosage details. The tablets should be stored in tightly closed containers at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The manufacturer is Prinston Laboratories in Charlotte, NC, and distribution is handled by Solco Healthcare US, LLC in Somerset, NJ. For more information, visit www.solcohealthcare.com/medguide/aripiprazole-tablets-pl.pdf.*

FDA Label Image

2 mg 30 Ct (Arpiprazole 2mg 100count)

This text provides information about Aripiprazole tablets, each containing 2 mg of the active ingredient. It also includes details on how to store the medication (20°C to 25°C), as well as information on dosages and indications. The text references a package insert for further details and mentions the website for more information. Additionally, it lists the manufacturer as Prinston Laboratories and the distributor as Solco Healthcare US, LLC.*

FDA Label Image

30 mg 30 Ct (Arpiprazole 30mg 100count)

This text provides important information about Aripiprazole tablets, each containing 30 mg of the active ingredient. It includes details on indications, dosage, storage conditions, and manufacturer information. The tablets should be stored in tightly closed containers within a specific temperature range. The package insert and a website link for further information are also provided. The tablets are distributed by Solco Healthcare in the USA.*

FDA Label Image

5 mg 30 Ct (Arpiprazole 5mg 100count)

This is a product information sheet for Aripiprazole tablets, each containing 5 mg. It provides details on storage conditions (20°C to 25°C), with excursions permitted between 15°C to 30°C. The text mentions to refer to the package insert for indications and dosage information. The tablets are manufactured by Prinston Laboratories in Charlotte, NC, and distributed by Solco Healthcare US, LLC in Somerset, NJ. It also includes a website link for more information and a reference number (9040693-01).*

FDA Label Image

Figure 1 (Figure1.png)

FDA Label Image

Figure 9 (Image 01)

This text presents a chart showing the mean change in YGTSS total tic score from baseline over weeks of treatment for patients receiving Aripiprazole low, Aripiprazole high, and placebo. The chart indicates the effectiveness of the treatments on reducing tic symptoms.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.